Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

CAR T-cell Therapy for Multiple Myeloma at Sheba

CAR T-Cell
Previously offered only to patients with leukemia and lymphoma, CAR T-cell therapy is now available as a treatment for multiple myeloma at Sheba.

CAR T-cell therapy is a revolutionary blood cancer treatment that helps the body combat tumors using its own T-cells. The therapy involves collecting the patient’s blood, separating T-cells, and genetically engineering them to produce chimeric antigen receptors (CARs). These allow the T-cells to recognize tumor cells, targeting and destroying them. After their alteration, T-cells are multiplied in a laboratory and then reintroduced to the patient’s body.

CAR T-cell therapy is a cutting-edge treatment available only at a limited number of cancer centers worldwide. At Sheba, CAR T-cell therapy has been offered since 2015, with over 220 patients who have undergone the therapy since. 

Until recently, Sheba offered CAR T-cell therapy for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. Following recent FDA approval, we are pleased to announce that CAR T-cell therapy is now available for the treatment of multiple myeloma patients.

By choosing Sheba for treatment, multiple myeloma patients can benefit from the experience of world-renowned specialists, including Prof. Arnon Nagler, President of the Hemato-Oncology Center, as well as end-to-end treatment in one facility.

Commenting on the addition of CAR T-cell therapy to the multiple myeloma therapeutic arsenal, Director of the Multiple Myeloma Unit at Sheba, Dr. Hila Magen, explained: “We are talking about an advanced immunotherapy that ‘re-educates’ the patient’s immune system to fight cancerous myeloma cells. It is truly an incredible breakthrough that opens the door for new multiple myeloma therapeutic approaches.” 

virtual care
Nuvo Group and Sheba Develop AI-Powered Gestational Diabetes Management Platform
A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba’s Beyond Virtual Hospital, simplifying care for pregnant…
Read More
pain treatment for pancreatic cancer
Breakthrough Study: Radiation Therapy Effective for Pain Management in Cancer Patients
Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much…
Read More
arc center
News Nov 30.
Real-Time Detection of Cancerous Biomarkers With Artificial Intelligence
Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all…
Read More